InnoCare Pharma's (HKG:9969, SHA:688428) phase II portion of the ongoing phase II/III adaptive study of soficitinib met its primary endpoint.
The drug showed meaningful improvements versus placebo for the treatment of adult patients with non-segmental vitiligo, according to a Thursday Hong Kong bourse filing.
Treatment with the drug also demonstrated consistent efficacy across multiple secondary endpoints.
The drug's safety profile is consistent with previous studies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments